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Abstract
Background: Liver failure (LF) is associated with prolonged hospital stay, increased cost and substantial mortality.
Due to the limited number of donor organs, extracorporeal liver support is suggested as an appealing concept to
“bridge to transplant” or to avoid transplant in case of recovery. ADVanced Organ Support (ADVOS) is a new type of
albumin dialysis, that provides rapid regeneration of toxin-binding albumin by two purification circuits altering the
binding capacities of albumin by biochemical (changing of pH) and physical (changing of temperature) modulation
of the dialysate.
It was the aim of this study to evaluate feasibility, efficacy and safety of ADVOS in the first 14 patients ever treated
with this procedure.
Methods: Patients included suffered from acute on chronic LF (n = 9) or “secondary” LF (n = 5) which resulted from
non-hepatic diseases such as sepsis. The primary endpoint was the change of serum bilirubin, creatinine and serum
BUN levels before and after the first treatment with ADVOS. The Wilcoxon Signed Rank test for paired samples was
used to analyze the data.
Results: A total of 239 treatments (1 up to 101 per patient) were performed in 14 patients (6 female, 8 male). Mean
age 54 ± 13; MELD-score 34 ± 7; CLIF-SOFA 15 ± 3. Serum bilirubin levels were significantly decreased by 32% during
the first session (26.0 ± 15.4 vs. 17.7 ± 10.5 mg/dl; p = 0.001). Similarly, serum creatinine (2.2 ± 0.8 vs. 1.6 ± 0.7 mg/dl;
p = 0.005) and serum BUN (49.4 ± 23.3 vs. 31.1 ± 19.7 mg/dl; p = 0.003), were significantly lowered by 27% and 37%,
respectively. None of the treatment sessions had to be interrupted due to side effects related to the procedure.
Conclusion: ADVOS efficiently eliminates water- and protein-bound toxins in humans with LF. ADVOS is feasible in
patients with advanced LF which is emphasized by a total number of more than 100 treatment sessions in one
single patient.
Keywords: Chronic liver failure, Acute-on-chronic-liver failure, Acute liver failure, Extracorporeal liver support, Liver
transplantation, Single pass albumin dialysis, Molecular Adsorbent Recirculating System, Fractionated plasma
separation and adsorption, CLIF-SOFA, MELD
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Background
Based on its course, liver failure (LF) is classified as
acute (ALF), chronic (CLF) or acute-on-chronic (ACLF)
[1–3]. In addition to the primary hepatic origin of LF,
“secondary” LF may result from non-hepatic diseases
such as sepsis [4]. All entities of LF are associated with
prolonged hospital stay, increased costs and substantial
mortality. LF of any origin frequently results in secondary
organ dysfunction, most commonly leading to renal, cir-
culatory and cerebral failure. Particularly in ACLF the
number of organ failures is associated with poor short-
term outcome approaching a 28-days- mortality of about
80% in ACLF if three or more organs fail [5]. In critically
ill patients, “secondary” LF contributes more to mortality
than any other organ failure, as demonstrated by a large
prospective multi-centric cohort study [4]. Furthermore,
any LF can progress to an irreversible state which requires
liver transplantation (LTX). Because of the limited number
of donor organs and contraindications to transplantation
in a substantial number of patients, extracorporeal liver
support (ELS) is considered an appealing concept to avoid
transplant in case of reversible LF or as a “bridge to trans-
plant”. This is further emphasized by a strong patho-
physiological rationale to remove toxic mediators which
frequently result in secondary failure of other organs.
Several concepts including single pass albumin dialysis
SPAD [6, 7], Molecular Adsorbent Recirculating System
(MARS;[7–16]), plasma exchange [17, 18], fractionated
plasma separation and adsorption [19] and bio-artificial
devices [20, 21] have been investigated. For most of
these procedures, improvement in secondary endpoints
has been demonstrated in pre-clinical trials and clinical
case series [6, 22, 23]. However, benefits regarding mor-
tality or other strong endpoints have not been proven
in a randomized controlled trial. With regard to multiple
confounders and modifiers of outcome in this particular
group of patients, a large number of patients would be
required for an appropriately powered randomized con-
trolled trial (RCT) using the currently available devices.
These large numbers of patients for such a RCT are
unlikely to be achieved due to treatment costs and
organizational expenses. Therefore, optimization of ELS
to increase its effect size and safety as well as offering
additional features for advanced multi-organ support to
enhance applicability might help to validate the clinical
usefulness of advanced ELS.
The ADVanced Organ Support (ADVOS) procedure is
a newly introduced ELS (ADVOS multi, manufactured
by Hepa Wash GmbH Munich, Germany), which poten-
tially offers multi-organ support facilities. Rapid de-
toxification and continuous regeneration of toxin-binding
albumin is provided by tertiary circuits, which alter the
binding capacities of albumin by biochemical (changing of
pH) and physical (change of temperature) modulation of
the effluent dialysate (Fig. 1; see Materials and Methods).
Feasibility and effective detoxification have been shown in
an animal study [24]. However, so far there were no reports
on ADVOS treatment in humans.
Therefore, it was the aim of our study to investigate the
efficacy of the elimination of bilirubin, creatinine and
BUN in the first 14 patients ever treated with the ADVOS
procedure.
Methods
Patients
The initial concept to evaluate the ADVOS procedure
comprised two separate randomized trials including pa-
tients with ACLF (HEPATICUS-1/Trial-Registration:
Fig. 1 The advanced organ support (ADVOS) device
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NCT01079091) and with “secondary” LF due to sepsis,
multi-organ failure or acute LF without cirrhosis
(HEPATICUS-2/Trial-Registration: NCT01079104). A
“run-in” phase with up to five patients per study was
part of the concept. These patients were not randomized,
but were treated according to the protocols for the treat-
ment groups of HEPATICUS-1 and −2. This approach was
approved by the local Ethics Committee (“Ethikkommis-
sion der Fakultät für Medizin der Technischen Universität
München”, reference number 2695/10; 2696/10). After
the run-in phase, the studies HEPATICUS-1 and
HEPATICUS-2 have not been continued due to lack of
feasibility of the trial-concept. This decision was also
based on the results of recently published randomized
trials on MARS and fractionated plasma separation and
adsorption. Consequently, the power calculation for
HEPATICUS-1 and −2 was reanalyzed. Using a more
“conservative” – i.e. pessimistic - estimation of the
effect-size also including the experiences from HELIOS
and RELIEF suggested that up to more than 700 pa-
tients might be needed for each trial.
The local Ethics Committee agreed on the evaluation of
the seven patients treated in the run-in-phase of these stud-
ies and of another seven patients who were treated after the
ADVOS procedure had received the CE-certificate in July
2013 (Ethikkommission der Fakultät für Medizin der Tech-
nischen Universität München”, reference number 18/15).
The need for informed consent was waived for the patients
after CE certification due to the retrospective design of the
study regarding those seven patients. Informed consent was
obtained from the seven patients included in the
HEPATICUS-trials or their legal representatives.
The study was conducted in an eight-bed general inten-
sive care unit of a German university hospital. Patients for
the HEPATICUS-trials were included between October
2012 and August 2012.
Inclusion criteria
Three patients of the run-in phase and six out of seven
patients included after CE-certification had ACLF ac-
cording to the CANONIC criteria [3, 25] and fulfilled all
mandatory criteria of the HEPATICUS-1 trial:
1. Documented clinical or histological evidence of
cirrhosis AND
2. Acute decompensation in previously stable cirrhotic
liver disease AND
3. Bilirubin ≥2 mg/dl AND
4. SOFA score ≥9 [26] calculated after 12 h of optimal
medical therapy AND
5. Patient is in the intensive care unit AND
6. Informed consent of the patient or the legal
representative AND
7. Age of 18 years or older AND
8. Enrollment of patients within 96 h of fulfilling
inclusion criteria 1–5
The inclusion criteria 6 and 8 were not mandatory for
the seven post-CE certification patients.
Five patients suffered from “secondary” liver failure de-
fined as acute liver failure of non-hepatic (e.g. sepsis,
shock) or hepatic (e.g. ASH) origin in patients without
evidence of chronic liver impairment. These patients ful-
filled all mandatory criteria of the HEPATICUS-2-trial:
1. Patient is in the intensive care unit AND
2. Bilirubin ≥2 mg/dl AND
3. SOFA score ≥9 calculated 12 h after initial
resuscitation measures AND
4. Signed informed consent of the patient or the legal
representative AND
5. Age of 18 years or older AND
6. Enrollment of patients within 96 h of fulfilling
inclusion criteria [1–5].
Criteria 4 and 6 were not mandatory for the post-CE
certification patients
For exclusion criteria see Table 1
The ADVOS procedure
The ADVOS multi device designed for extracorporeal
liver and kidney support was used for all treatments.
The device is composed of three circuits: A blood circuit
to perfuse a commercially available dialyzer (FX 80;
Fresenius Medical Care; D-61352 Bad Homburg;
Germany) was established using a conventional double-
lumen dialysis catheter (Gambro Gam Cath Dolphin;
Gambro Hospal GmbH, Gröbenzell, Germany). Catheters
with a length of 250 mm and a diameter of 13 F were
used for femoral access and catheters with a length of
150–175 mm and a diameter of 13 F were used for in-
ternal jugular access, respectively. The primary and sec-
ondary circuits were established using a commercially
available CRRT device (CF 200, Infomed SA, Geneva,
Switzerland).
The second circuit was perfused by the albumin dialys-
ate running on the dialysate side of the dialyzer in paral-
lel with the blood flow. According to the information of
the manufacturer several ex-vivo experiments had
shown that for the elimination of protein-bound toxins
concurrent flow is not inferior to countercurrent flow.
The recycled albumin containing dialysate has a volume
of approximately 2 liters. The composition of albumin
dialysate was similar to a conventional hemodialysis di-
alysate with the only exception of addition of human al-
bumin with an end-concentration of 2–4%.
The third circuit represents the proprietary ADVOS
procedure and aims at regeneration and detoxification
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of toxin-loaded albumin. In this ADVOS circuit, the
toxin-loaded albumin effluent from the dialyzer is
branched into two parts. Each part undergoes a change
of pH by adding acid or base before passing through
the dialyzers resulting in a release of albumin-bound
toxins in the dialysate. The unbound toxins are re-
moved by a tertiary filtration process. Finally, the acid-
ified and the alkalinized albumin dialysates converge so
that an albumin dialysate with physiological pH (range
6.9–7.6) is generated again. In addition to biochemical
modulation of the binding capacities of albumin, the
ADVOS procedure also provides physical altering of al-
bumin binding by heating and cooling of the dialysate.
The primary temperature modulation can be performed
by cooling of the dialysate to 28°. To keep this modula-
tion “regional” the re-transfused blood is re-warmed to
the pre-treatment body-temperature. Irrespective of our
study – in which no systemic modulations of blood
temperature were performed – this feature also allows for
modulation of the body temperature (heating or cooling
of the patient), if this is considered useful within the
multi-organ support facilities of the ADVOS device.
Finally, the de-toxified dialysate containing unloaded
albumin re-circles to the affluent connector of the di-
alysate compartment of the dialyzers.
Anticoagulation
Anticoagulation was performed as required for conven-
tional dialysis and modified for the patients’ individual
coagulation state at the discretion of the treating
physician.
Pre- and post-dilution
No pre- or post-dilution was used during any treatment
session.
Length of treatment session
For ethical reasons and to optimize the individual thera-
peutic effect, there was no strictly pre-defined treatment
period. Regarding the available experience with other de-
vices for liver support the protocol aimed at treatment
periods of 6–12 h which were achieved in the majority
of first treatment sessions (see Table 3). Taking into con-
sideration the disease severity of most of the patients,
the treatment periods were modified according to other
diagnostic or therapeutic requirements and according to
the individual condition of the patient.
During ADVOS therapy no additional renal replace-
ment therapy (serial or in parallel) was performed.
Table 1 Exclusion criteria of HEPATICUS-1 and of HEPATICUS-2 trial
Exclusion criteria for both HEPATICUS-1 and HEPATICUS-2
Patients, whose mortality approaches 100%, or who are not likely to benefit from treatment
(intervention with ADVOS is likely to be futile)
Patients, whose current medical condition does not allow treatment with any extracorporeal procedure
Potential conflict with good clinical practice (GCP) or with the declaration of Helsinki
PaO2/FiO2≤ 100 mmHg (respiratory SOFA score of 4)
Patient testament excludes the use of life-prolonging measures
Post-operative patients whose liver failure is related to liver surgery
Participation in another clinical study
Patients diagnosed with Creutzfeldt-Jakob disease
Pregnancy
Weight ≥120 kg
Uncontrolled seizures
Mean arterial pressure ≤50 mmHg despite conventional medical treatment
Active or uncontrolled bleeding
Untreatable extrahepatic cholestasis
Patients with MELD-score of 40
Exclusion criteria specific for HEPATICUS-1 Exclusion criteria specific for HEPATICUS-2
Patients with creatinine >5 mg/dl or urine output <200 ml/day
(renal SOFA-score of 4)
Patient with known history of chronic liver disease
Patients who receive a vasopressor support of Dopamine >15 μg/kg/min or epinephrine
>0.1 μg/kg/min or norepinephrine >0.1 μg/kg/min (cardiovascular SOFA-score of 4)
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Endpoints
With regard to efficacy and “proof of concept”, a com-
parison of pre- and post-treatment values of bilirubin,
creatinine and blood urea nitrogen (BUN) was chosen as
the primary endpoint. These blood analyses were per-
formed immediately before connection and after discon-
nection to the ADVOS procedure. Due to the markedly
different number of treatment sessions (1–101), analyses
regarding the primary endpoint was restricted to the first
treatment session in each patient.
Statistics
The Wilcoxon-Test for paired samples was used to detect
significant treatment effects. Spearman correlation
was calculated to analyze the association of absolute
and relative decreases in bilirubin, creatinine and BUN.
P-values <0.05 were considered as statistically significant.
All statistical tests were performed using IBM SPSS
Statistics 23 (SPSS Inc., Chicago, IL, USA).
Results
Patients’ characteristics
The patients’ characteristics are shown in Table 2.
All patients were critically ill with a high predicted
mortality according to different scores of HF and general
prognostic scores for critically ill patients: All but one
patient with ACLF had the highest score of the
CANONIC-ACLF staging (stage C) [3]. The MELD-
score [27] in these patients was 34 ± 7 points. The mean
CLIF-SOFA [3] was 15 ± 3 points. Only two patients
were listed for liver transplant. None of the patients
underwent liver transplantation due to unavailable organ
or acute contraindications for transplantations.
The most frequent precipitating event of ACLF was
acute alcoholic hepatitis in four of nine cases. Two more
cases of ACLF were related to infectious complications.
Another two patients without ACLF suffered from first
episodes of alcoholic steatohepatitis without evidence of
cirrhosis which precludes listing for liver transplantation
for six months according to German allocation laws.
The other three cases of secondary LF were induced by
sepsis. Among those patients were two patients with
malignancies.
All 14 patients suffered from acute renal failure ac-
cording to the AKIN criteria. Seven of 14 patients had
undergone renal replacement therapy before the first
ADVOS treatment.
Primary endpoint: treatment efficacy
The 14 first treatment sessions were performed for a
mean of 575 ± 193 min without interruption or need for
disconnection due to technical reasons or adverse events
related to the procedure. The serum levels of both
protein-bound and water-soluble toxins were signifi-
cantly decreased during treatment with the ADVOS pro-
cedure: Se5rum bilirubin levels were significantly
decreased by 32% after a single ADVOS procedure (17.7
± 10.5 mg/dl vs. 26.0 mg/dl ± 15.4 mg/dl; p = 0.001).
Similarly, serum creatinine (1.6 ± 0.7 mg/dl vs. 2.2 ±
0.8 mg/dl; p = 0.005) and BUN (31.1 ± 20.29 mg/dl vs.
49.4 ± 23.3 mg/dl; p = 0.003) were significantly lowered
by a mean of 27% and 37% by a single ADVOS treat-
ment, respectively (Table 3; Figs. 2, 3 and 4).
Treatment efficacy at different starting values
There was a significant correlation between the baseline
serum levels of bilirubin, creatinine and BUN with their
absolute reduction induced by the first ADVOS treat-
ment (r = 0.911, p < 0.001; r = 0.756, p = 0.002; r = 0.644,
p = 0.013), respectively (see also Table 3). By contrast,
the relative changes in serum bilirubin, creatinine and
BUN were not associated to their baseline levels (r =
0.383 p = 0.177; r = 0.236 p = 0.417; r = 0.247 p = 0.395).
Safety and outcome
In summary, the ADVOS treatment was
hemodynamically well tolerated during a mean of 9.7 ±
3.5 h of therapy. Overall, 239 treatments were carried
out (17 ± 26; 1–101 treatments per patient). None of the
treatment sessions had to be interrupted due to compli-
cations that were likely related to the ADVOS proced-
ure. The 28-days survival rate was 5/15 (36%). Finally,
two patients (14%) were discharged home.
Discussion
At present, there are three procedures of extracorporeal
liver support based on albumin-dialysis used in clinical
practice. Albumin-dialysis aims at the elimination of
albumin-bound endogenous toxins such as bile-acids
that accumulate in case of LF via a semipermeable mem-
brane. For this purpose, albumin has to be added to the
dialysate in a final concentration between 2% and 20%
[6, 7, 10, 11, 28]. In SPAD, dialysate flow rates range be-
tween 0.5 L/h and 2 L/h. SPAD is easily available, can be
performed with standard renal replacement therapy
(RRT) devices and has the advantage of “naïve” albumin
in the dialysate which provides maximum detoxification
capacities of the dialysate [6]. However, with repeated
treatment sessions up to 24 h and a market price of
commercially available 20% human albumin solutions up
to 150€ per 100 mL, a total albumin cost of approxi-
mately 1500€ per session has been estimated [6]. There-
fore, attempts have been made to recirculate albumin
after regeneration (cleansing). MARS, the second type of
albumin-dialysis, helps to save albumin resources. Its
efficacy in elimination of albumin bound toxins has
been demonstrated in several case-series and studies
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[7, 10, 11, 28]. While MARS uses a charcoal column and
an anion exchange resin column to unload albumin-
bound toxins and to regenerate albumin, the recently
introduced ADVOS procedure continuously unloads
and regenerates albumin by intermittent alteration of
its binding capacities [7, 10, 11, 24, 28]. This is achieved
by biochemical (changing of pH) and physical (change
of temperature) modulation of the effluent dialysate. In
addition to its features as ELS, ADVOS – at least from
a theoretical viewpoint - offers the advantage of multi-
organ support by providing the potential to modulate
the acid–base-balance and the body temperature of the
patient. While MARS is usually performed with 600 mL
of 20% albumin, this amount is further reduced in the
ADVOS procedure to 200 mL [24].
Nevertheless, similar to MARS, regeneration of albu-
min carries the potential for its denaturation and loss of
efficacy.
Our study in 14 patients primarily analyzed the effi-
cacy of elimination of protein-bound and water-soluble
Fig. 2 Boxplots depicting the time course of serum bilirubin
Fig. 3 Boxplots depicting the time course of serum creatinine
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toxins by the ADVOS procedure. As demonstrated in
Table 2 and Table 4, ADVOS significantly reduced
serum bilirubin, creatinine and BUN by 32%, 27% and
37%, respectively. Although cross-comparison with data
from other recent studies with different inclusion criteria
and populations has to be performed with caution, our
data suggest at least comparable elimination capacities
of ADVOS to those reported for MARS, fractionized
plasma separation and adsorption (Prometheus) and
SPAD in the most recent studies (Table 4). Furthermore,
Fig. 4 Boxplots depicting the time course of serum BUN
Table 4 Comparison of patients’ characteristics and elimination efficacy
Trial/Reference Banares [10] Kribben [19] Sponholz MARS [7] Sponholz SPAD [7] Own study
Device MARS Prometheus MARS SPAD ADVOS
Patients’ characteristics
Clinical setting 19 ICUs 10 ICUs Surgical ICU Medical ICU
Type of LF
- ACLF 100% 100% 56% 64%
- ALF - - 28% -
- “secondary” LF - - - 36%
- Graft failure - - 16% -
(CLIF)-SOFA 8 ± 3 10 ± 3 13 ± 4 15 ± 3
MELD 26 ± 8 28 ± 10 34 ± 7
Child-Pugh 11 ± 2 12 ± 1 12 ± 1
Efficacy analysis
No. of treatments for efficacy analysis 4 8 (mean) 2.2 (mean) 2.2 (mean) 1
Delta-Bilirubin relative −26% (day 4) −23% (day 28) −23% −23% −32%
Delta-Bilirubin absolute [mg/dL] −8.7 (day 4) −6 (day 28) −4.3 −4.2 −8.3
Delta-creatinine relative −20% (day 4) −13% (day 28) −18% +5% −27%
Delta-creatinine absolute [mg/dL] −0.3 (day 4) −0.2 (day 28) −0.4 +0.1 −0.6
Delta-BUN relative n.d. n.d. −9% +5% −37%
Delta-BUN absolute [mg/dL] n.d n.d. −12 +8 −18
Maximum number of treatments 10 11 4 4 101
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it has to be kept in mind that these elimination rates
were achieved by a single ADVOS treatment compared
to repeated (two up to eight) sessions performed in the
reference studies with the other devices. Treatment pe-
riods between seven and ten hours were comparable for
all methods.
Similarly, the interpretation of feasibility and safety
data is limited due to the small number of patients
treated and due to the lack of a direct control group.
However, our conclusions are supported by the high
number of total treatment sessions that was done reach-
ing up to 101 sessions in one single patient.
Although we have to clearly admit that this study was
not powered for mortality analysis and lacked a control
group, the final outcome of the patients is worth men-
tioning. Due to the lack of direct controls, the outcome
of our patients has to be compared to the data available
from large scoring databases (e.g. CLIF-SOFA). These
databases provide validated outcome estimates for patients
comparable those in our study. At first glance, survival was
poor with 28-days and in-hospital mortality rates of 65%
and 86%, respectively. This might be related to several
reasons: As supported by all scoring systems investi-
gated, the patients were more severely ill compared to
the randomized trials summarized in Table 4. All but
one patient with ACLF had Grade 3 according to the
CANONIC criteria, which has been associated in a re-
cent study with 28-days- and 3-months-mortality rates
of 83.6% and 87.3%, respectively [5]. For the mean
CLIF-SOFA score of 15 points in our patients, the same
study predicts a high 28-days-mortality approaching
90%. Furthermore, two of our patients suffered from
malignancies, and in at least five patients active alco-
holism was suggested by the presence of ASH. Ongoing
alcoholism - precluding LTX according to German allo-
cation rules – was also evident in three patients with
ACLF. Two patients suffered from “secondary” (see above)
liver failure due to severe sepsis and was classified as non-
transplantable. This may explain why only two patients
were listed for liver transplantation. None of these patients
underwent LTX during the observation period. These in-
dividual medical histories emphasize that extracorporeal
liver support was initiated in most of our patients as a res-
cue treatment, since LTX was not feasible.
Strengths and limitations of the study
This study demonstrated feasibility and efficacy of a new
approach to ELS. To the best of our knowledge a total
number of 101 treatment sessions in one single patient
has not been reported for any other procedure of ELS.
Elimination rates for surrogate markers were among the
highest ever reported (Table 4) suggesting a high efficacy
during the first treatment. The patients included are
heterogenous regarding the aetiology of liver failure and
also regarding the number of treatment sessions. This
heterogeneity could be considered as a methodological
limitation. On the other hand, this heterogeneity might
give first hints on potential indications and general applic-
ability of the procedure in different groups of patients with
severe liver failure. Furthermore, any reporting bias could
be avoided, since we reported on all patients who have
ever been treated with ADVOS in our ICU. Despite feasi-
bility, safety and efficacy of the intervention, the overall
outcome was poor, which might be related to the use of
ADVOS as a rescue therapy in this study which predom-
inantly included patients without the option to undergo
LTX. Another limitation is the low number of patients in-
cluded that precludes more robust conclusions regarding
the outcome. Conclusions regarding the outcome are fur-
ther limited by the lack of a randomized control group or
matched controls. Finally, even in case of randomized
controls the statistical power would be low due to the re-
stricted number of comparisons.
Conclusion
ADVOS efficiently eliminates water- and protein-bound
toxins in humans with LF. ADVOS is feasible in patients
with advanced LF which is emphasized by a total number
of more than 100 treatment sessions in one single patient.
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